Baylor College of Medicine: Car T Cell Therapy Targeting HER2 Antigen Shows Promise Against Advanced Sarcoma in Phase I Trial
April 25, 2024
April 25, 2024
HOUSTON, Texas, April 25 (TNSres) -- The Baylor College of Medicine issued the following news:
Researchers at Texas Children's Cancer Center and the Center for Cell and Gene Therapy at Baylor College of Medicine, Texas Children's Hospital and Houston Methodist published results of a phase I clinical trial of a novel immunotherapy for high-risk sarcomas in the journal Nature Cancer.
The therapy uses chimeric antigen receptor (CAR) T cells engineered to target the HER2 pr . . .
Researchers at Texas Children's Cancer Center and the Center for Cell and Gene Therapy at Baylor College of Medicine, Texas Children's Hospital and Houston Methodist published results of a phase I clinical trial of a novel immunotherapy for high-risk sarcomas in the journal Nature Cancer.
The therapy uses chimeric antigen receptor (CAR) T cells engineered to target the HER2 pr . . .